



# MedCannAccess®

401-5359 Dundas St. W.  
Toronto, ON M9B 1B1

December 17, 2014 – Toronto, ON

FOR IMMEDIATE RELEASE

## MedCannAccess Partners with CannScience on Non-Smoked Forms of Marijuana

MedCannAccess is excited to announce it has acquired a substantial minority equity stake in CannScience Innovations Inc. (CannScience), a leading cannabinoid drug development firm. This partnership positions MedCannAccess to be a leader in the development of pharmaceutical cannabinoid products.

“Successful companies in the cannabis industry will have three legs to their platform: quality production, an effective patient acquisition and retention strategy, and innovative research and development capabilities,” said Rade Kovacevic, VP Business Development at MedCannAccess. “We believe we have strong positions already in the first two legs, and through this investment, we have solidified the R&D piece of our platform, positioning us as a leader in future cannabinoid drug development. Physicians and patients alike have been calling for access to cannabinoid products that do not require smoking or inhalation and are delivered in metered doses; this partnership will allow us to take that significant step forward.”

CannScience is an R&D biopharmaceutical company established in Toronto, Canada to conduct research and product development for extracts and formulations related to medical cannabis and its derivatives. CannScience is developing proprietary technologies and owns know-how related to the chemistry and pharmacology of cannabinoids and potentially how they integrate with various medical devices and drug delivery technologies. CannScience intends to develop commercial ready products and obtain regulatory approval for RapidMist™ in the Canadian and international jurisdictions. The company’s founders have a wealth of experience in the life sciences industry and access to laboratories at some of the top research institutions in Canada.

“CannScience is working to develop its product pipeline which will include proprietary drug, device, and delivery technologies” said Har Grover, the CEO of CannScience. On November 18, 2014, CannScience Innovations Inc. entered into a non-binding Letter of Intent (LOI) with GenereX Biotechnology Corporation ([www.genereX.com](http://www.genereX.com)) (OTCBB: GNBT) to license the Company's proprietary RapidMist™ drug delivery technologies to CannScience for the buccal delivery of cannabis derived products into the bloodstream.

MedCannAccess was established to provide access to the highest-quality of medical cannabis products developed through research and innovation, aiming to improve the quality of life for persons with a wide range of conditions including chronic disabilities and terminal illnesses. MedCannAccess is a proud member of the Canadian Medical Cannabis Industry Association, Toronto Board of Trade, Guelph Chamber of Commerce and Ontario Chamber of Commerce.

-30-

Media Contact:

Rade Kovacevic, VP Business Development, MedCannAccess, 519-780-7830

1-877-780-6337

[www.MedCannAccess.com](http://www.MedCannAccess.com)

8437726 Canada Inc. o/a MedCannAccess